The_Assassin
liked and commented on
$Fusemachines (FUSE.US)$ ripping from $1.68 entry
The_Assassin
liked and commented on
$iSpecimen (ISPC.US)$ another banger . Hope you made some cash , went 25% not bad . could still move more . destroy the like so i know my posts helps atleast someone .
For more real time alerts check the bio
For more real time alerts check the bio
8
4
The_Assassin
liked and commented on
$iSpecimen (ISPC.US)$ top pick at $0.19
6
9
The_Assassin
liked
What do you have ? 25 likes I will reveal my top pick
$iSpecimen (ISPC.US)$
$U Power (UCAR.US)$
$Xiao-I (AIXI.US)$
$Erayak Power Solution Group (RAYA.US)$
$Generation Income Properties (GIPR.US)$
$DarkIris (DKI.US)$
$GameSquare (GAME.US)$
$iSpecimen (ISPC.US)$
$U Power (UCAR.US)$
$Xiao-I (AIXI.US)$
$Erayak Power Solution Group (RAYA.US)$
$Generation Income Properties (GIPR.US)$
$DarkIris (DKI.US)$
$GameSquare (GAME.US)$
48
12
$XCF Global (SAFX.US)$ solid news, lets see
XCF Global, BGN agree binding term sheet for Reno renewable fuel tolling, broader global SAF distribution and logistics partnership
– New Rise Renewables Reno conversion remains on schedule, targeting commissioning in early June 2026.
– Key catalyst deliveries expected in late May and early June 2026 to support commissioning.
XCF Global, BGN agree binding term sheet for Reno renewable fuel tolling, broader global SAF distribution and logistics partnership
– New Rise Renewables Reno conversion remains on schedule, targeting commissioning in early June 2026.
– Key catalyst deliveries expected in late May and early June 2026 to support commissioning.
2
3
$Nexalin Technology (NXL.US)$ solid news over $0.49
Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
2
$Galmed Pharmaceuticals (GLMD.US)$ entry over $1
Today, 7:35 AM: Galmed develops brain-penetrating nanoparticle Aramchol for Parkinson’s, co-developed with Barcode Nanotech, plans PoC Ph1b/2 PD trial in H2 2026
Today, 7:35 AM: Galmed develops brain-penetrating nanoparticle Aramchol for Parkinson’s, co-developed with Barcode Nanotech, plans PoC Ph1b/2 PD trial in H2 2026
2
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)